Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer

被引：5
|
作者：
Cao, Yi [1 ,2 ]
Li, Yunjin [1 ,2 ]
Liu, Ruijie [1 ]
Zhou, Jianhua [1 ,2 ]
Wang, Kuansong [1 ,2 ]
机构：
[1] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Peoples R China
[2] Cent South Univ, Sch Basic Med Sci, Dept Pathol, Changsha 410008, Peoples R China
来源：
CANCERS | 2023年 / 15卷 / 09期
基金：
中国国家自然科学基金;
关键词：
HER2-positive breast cancer; targeted therapy; resistance; anti-resistance; TRASTUZUMAB RESISTANCE; PROMOTES RESISTANCE; MONOCLONAL-ANTIBODY; SPLICE VARIANT; PHASE-II; HER2; GROWTH; EXPRESSION; LAPATINIB; CELLS;
D O I：
10.3390/cancers15092568
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The amplification of epidermal growth factor receptor 2 (HER2) is associated with a poor prognosis and HER2 gene is overexpressed in approximately 15-30% of breast cancers. In HER2positive breast cancer patients, HER2-targeted therapies improved clinical outcomes and survival rates. However, drug resistance to anti-HER2 drugs is almost unavoidable, leaving some patients with an unmet need for better prognoses. Therefore, exploring strategies to delay or revert drug resistance is urgent. In recent years, new targets and regimens have emerged continuously. This review discusses the fundamental mechanisms of drug resistance in the targeted therapies of HER2positive breast cancer and summarizes recent research progress in this field, including preclinical and basic research studies.
引用
收藏
页数：27
相关论文
共 50 条
  • [1] Overcoming Treatment Resistance in HER2-Positive Breast Cancer Potential Strategies
    Puglisi, Fabio
    Minisini, Alessandro Marco
    De Angelis, Carmine
    Arpino, Grazia
    DRUGS, 2012, 72 (09) : 1175 - 1193
  • [2] Mechanisms of Resistance to HER2-Targeted Therapies in HER2-positive Breast Cancer
    Veeraraghavan, Jamunarani
    Liao, Fu-Tien
    Qin, Lanfang
    Gordon, Tia
    Raghavan, Alekya
    Sabotta, Caroline
    Kaplan, Rachel
    Gutierrez, Carolina
    Osborne, C. Kent
    Rimawi, Mothaffar F.
    Schiff, Rachel
    CANCER RESEARCH, 2024, 84 (03)
  • [3] Emerging Targeted Therapies for HER2-Positive Breast Cancer
    Florencia Mercogliano, Maria
    Bruni, Sofia
    Luciana Mauro, Florencia
    Schillaci, Roxana
    CANCERS, 2023, 15 (07)
  • [4] Overcoming resistance in Her2-positive metastatic breast cancer
    Oksuzoglu, Omur Berna
    LEUKEMIA RESEARCH, 2018, 73 : S13 - S13
  • [5] Overcoming Treatment Resistance in HER2-Positive Breast CancerPotential Strategies
    Fabio Puglisi
    Alessandro Marco Minisini
    Carmine De Angelis
    Grazia Arpino
    Drugs, 2012, 72 (9) : 1175 - 1193
  • [6] Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review
    Schramm, Amelie
    De Gregorio, Nikolaus
    Widschwendter, Peter
    Fink, Visnja
    Huober, Jens
    BREAST CARE, 2015, 10 (03) : 173 - 178
  • [7] Advanced HER2-positive breast cancer: Overcoming treatment resistance
    Rimawi, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [8] Novel HER2-targeted therapies for HER2-positive metastatic breast cancer
    Kunte, Siddharth
    Abraham, Jame
    Montero, Alberto J.
    CANCER, 2020, 126 (19) : 4278 - 4288
  • [9] Recent advances in novel targeted therapies for HER2-positive breast cancer
    Murphy, Conleth G.
    Morris, Patrick G.
    ANTI-CANCER DRUGS, 2012, 23 (08) : 765 - 776
  • [10] HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
    Pernas, Sonia
    Tolaney, Sara M.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
12345